The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2°P-TIMI 50
Open accessAbstract
Background—: Vorapaxar is a novel antagonist of protease-activated receptor-1, the primary receptor for thrombin on human platelets that is also present on vascular endothelium and smooth muscle. Patients with peripheral artery disease are at risk of systemic atherothrombotic events, as well as acute and chronic limb ischemia and the need for peripheral revascularization. Methods and Results—: The Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA2°P-TIMI 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in 26 449 patients with stable atherosclerotic vascular disease (myocardial infarction, stroke, or peripheral artery disease). Patients with qualifying peripheral artery disease (n=3787) had a history of claudication and an ankle-brachial index of <0.85 or prior revascularization for limb ischemia. The primary efficacy end point was cardiovascular death, myocardial infarction, or stroke, and the principal safety end point was Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) bleeding. In the peripheral artery disease cohort, the primary end point did not differ significantly with vorapaxar (11.3% versus 11.9%; hazard ratio, 0.94; 95% confidence interval, 0.78–1.14; P =0.53). However, rates of hospitalization for acute limb ischemia (2.3% versus 3.9%; hazard ratio, 0.58; 95% confidence interval, 0.39–0.86; P =0.006) and peripheral artery revascularization (18.4% versus 22.2%; hazard ratio, 0.84; 95% confidence interval, 0.73–0.97; P =0.017) were significantly lower in patients randomized to vorapaxar. Bleeding occurred more frequently with vorapaxar compared with placebo (7.4% versus 4.5%; hazard ratio, 1.62; 95% confidence interval, 1.21–2.18; P =0.001). Conclusions—: Vorapaxar did not reduce the risk of cardiovascular death, myocardial infarction, or stroke in patients with peripheral artery disease; however, vorapaxar significantly reduced acute limb ischemia and peripheral revascularization. The beneficial effects of protease-activated receptor-1 antagonism on limb vascular events were accompanied by an increased risk of bleeding. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00526474.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Self-citationDennis, M. S. (1996) · The Lancet · Cited by 2,728
Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease
Criqui, M. H., Langer, R. D., Fronek, A., Feigelson, H. S., Klauber, M. R., McCann, T. J., & Browner, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202063260605 · Cited by 2,579
Platelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135
The way I see it: House officers need formal career development
Connor, A. (2002) · BMJ · doi:10.1136/bmj.324.7336.s71 · Cited by 1,143
Protease‐activated receptors in hemostasis, thrombosis and vascular biology
COUGHLIN, S. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01377.x · Cited by 1,035
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
Morrow, D. A., Braunwald, E., Bonaca, M. P., Ameriso, S. F., Dalby, A. J., Fish, M. P., Fox, K. A. A., Lipka, L. J., Liu, X., Nicolau, J. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200933 · Cited by 948
Self-citationRooke, T. W., Hirsch, A. T., Misra, S., Sidawy, A. N., Beckman, J. A., Findeiss, L. K., Golzarian, J., Gornik, H. L., Halperin, J. L., Jaff, M. R., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.023 · Cited by 924
Self-citationBhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.03.025 · Cited by 805
Self-citationBhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Fowkes, F. G. R. (2010) · JAMA · doi:10.1001/jama.2010.221 · Cited by 624
The Epidemiology of Peripheral Arterial Disease: Importance of Identifying the Population at Risk
Criqui, M. H., Denenberg, J. O., Langer, R. D., & Fronek, A. (1997) · Vascular Medicine · doi:10.1177/1358863x9700200310 · Cited by 447
Pande, R. L., Perlstein, T. S., Beckman, J. A., & Creager, M. A. (2011) · Circulation · doi:10.1161/circulationaha.110.003954 · Cited by 406
Self-citationPatients with peripheral arterial disease in the CHARISMA trial
Cacoub, P. P., Bhatt, D. L., Steg, P. G., Topol, E. J., Creager, M. A., & for the CHARISMA Investigators (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn534 · Cited by 360
Self-citationBerger, J. S., Krantz, M. J., Kittelson, J. M., & Hiatt, W. R. (2009) · JAMA · doi:10.1001/jama.2009.623 · Cited by 360
Mahoney, E. M., Wang, K., Keo, H. H., Duval, S., Smolderen, K. G., Cohen, D. J., Steg, G., Bhatt, D. L., Hirsch, A. T., & on behalf of the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators* (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.930735 · Cited by 256
Antithrombotic Therapy in Peripheral Artery Disease
Alonso-Coello, P., Bellmunt, S., McGorrian, C., Anand, S. S., Guzman, R., Criqui, M. H., Akl, E. A., Vandvik, P. O., Lansberg, M. G., Guyatt, G. H., et al. (2012) · Chest · doi:10.1378/chest.11-2307 · Cited by 198
Morrow, D. A., Scirica, B. M., Fox, K. A. A., Berman, G., Strony, J., Veltri, E., Bonaca, M. P., Fish, P., McCabe, C. H., & Braunwald, E. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.06.027 · Cited by 172
Self-citationPatterson, C., Stouffer, G. A., Madamanchi, N. R., & Runge, M. S. (2001) · Circulation Research · doi:10.1161/hh1001.091447 · Cited by 140
Antiplatelet agents for intermittent claudication
Wong, P. F., Chong, L. Y., Mikhailidis, D. P., Robless, P. A., & Stansby, G. P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001272.pub2 · Cited by 68
Achterberg, S., Visseren, F. L. J., Kappelle, L. J., Pruissen, D. M. O., van der Graaf, Y., & Algra, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04437.x · Cited by 12
Cited by
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.007 · Cited by 1,941
Self-citationGerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000470 · Cited by 1,055
Self-citationRivaroxaban in Peripheral Artery Disease after Revascularization
Bonaca, M. P., Bauersachs, R. M., Anand, S. S., Debus, E. S., Nehler, M. R., Patel, M. R., Fanelli, F., Capell, W. H., Diao, L., Jaeger, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2000052 · Cited by 1,045
Self-citationGerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000471 · Cited by 1,020
Self-citation
Metadata
- Authors
- Bonaca, M. P., Scirica, B. M., Creager, M. A., Olin, J., Bounameaux, H., Dellborg, M., Lamp, J. M., Murphy, S. A., Braunwald, E., & Morrow, D. A.
- Venue
- Circulation
- Published
- 2013-04-09
- Volume
- 127
- Issue
- 14
- Pages
- 1522-1529
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2044658006
- Cited by
- 305
- References
- 25
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.